Pembrolizumab Plus ICE: ‘Acceptable’ Salvage for Relapsed/Refractory Hodgkin Lymphoma
Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”
Diagnosis & Disease Information
Tumor Microenvironment Cellular Makeup May Predict Nivolumab Response for Patients With Hodgkin Lymphoma
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Interleukin-6 Levels May Predict PFS in Relapsed/Refractory Hodgkin Lymphoma Treated With Nivolumab
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
Nivolumab Rechallenge May Benefit Patients With Relapsed, Refractory Hodgkin Lymphoma
Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.
Radiotherapy May Confer Small Risk of Cardiovascular Disease in Early-Stage Hodgkin Lymphoma
The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.
Patients With Lymphoma May Develop Antibodies for COVID-19 Vaccine 6 Months After Treatment
Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.
Treatment Impacts on Fertility for Patients With Hodgkin Lymphoma or Diffuse Large B-Cell Lymphoma
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
Regimen Deemed Safe, Effective as Bridge to Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma
The overall response rate was 100%.
Tislelizumab Deemed an ‘Important Option’ for Relapsed/Refractory Classical Hodgkin Lymphoma
The median overall survival was not reached at 3 years.
Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...